SEP 4·SEC EDGARLow
Kalinichev Mikhail sold (to issuer) 306,765 shares of ADXN
Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ADXN
Addex Therapeutics Ltd.
Price · $ADXNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ADXN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- — 7 txs
Hill Raymond George1× · —
10b5-1 share of filings0%
Top stories · $ADXNMore →
SEP 4·SEC EDGAR
Nunn Jason Raleigh sold (to issuer) 219,561 shares of ADXN
Nunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
SEP 4·SEC EDGAR
Mills Roger sold (to issuer) 392,837 shares of ADXN
Mills Roger (CHIEF MEDICAL OFFICER) sold (to issuer) 392,837 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
ADXN sentiment & insider activity
Recent ADXN coverage spans insider activity, technology and earnings.
In the last 30 days, ADXN insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales. The most active reporter was Hill Raymond George with 1 filing.
What's driving ADXN
Insider sale may signal lack of confidence, but size is modest for a micro‑cap.
Insider sale may signal lack of confidence, but the amount is modest for a biotech and likely has limited price impact.
Insider sale may signal reduced confidence or simply portfolio rebalancing; limited price impact expected.
The insider sale may signal lack of confidence and could pressure the stock lower.
Large insider sell may signal negative sentiment and could pressure the stock lower in the short term.
alphai scores every news story that mentions ADXN with an AI model for sentiment and relevance, and aggregates insider trades from Addex Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ADXN
Score
Kalinichev Mikhail sold (to issuer) 306,765 shares of ADXN
Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readNunn Jason Raleigh sold (to issuer) 219,561 shares of ADXN
Nunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readMills Roger sold (to issuer) 392,837 shares of ADXN
Mills Roger (CHIEF MEDICAL OFFICER) sold (to issuer) 392,837 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readManke Isaac sold (to issuer) 219,561 shares of ADXN
Manke Isaac sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readLawton Vincent Michael sold (to issuer) 2,507,487 shares of ADXN
Lawton Vincent Michael sold (to issuer) 2,507,487 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readHill Raymond George sold (to issuer) 1,365,532 shares of ADXN
Hill Raymond George sold (to issuer) 1,365,532 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readDyer Timothy Mark sold (to issuer) 16,413,787 shares of ADXN
Dyer Timothy Mark (CHIEF EXECUTIVE OFFICER) sold (to issuer) 16,413,787 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readAddex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation
Addex Therapeutics (ADXN) said preclinical rat research published in the International Journal of Neuropsychopharmacology found its mGlu7 NAM ADX71743 increased wakefulness and reduced REM and non-REM sleep, while changing stress-related neurotransmitters across brain regions. The company said results support its mGlu7 program being advanced by Neurosterix. ADXN last traded at $5.79, premarket $6.19.
3 min readAddex Therapeutics: Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN) said preclinical research published in the International Journal of Neuropsychopharmacology shows its mGlu7 negative allosteric modulator ADX71743 alters sleep-wake regulation in rats, increasing wakefulness and reducing REM and non-REM sleep, and changes stress-related neurotransmitters. The company links results to the rationale for its mGlu7 program via Neurosterix.
4 min read
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Addex Therapeutics reported Q1 2026 results and a corporate update. The company said its spin-out Neurosterix is on track to complete Phase 1 in July for NTX-253, an M4 positive allosteric modulator for schizophrenia. Q1 2026 net loss was CHF 1.712m vs CHF 1.473m in Q1 2025; cash fell to CHF 0.935m from CHF 2.825m.
6 min read